FAM13A polymorphism is associated with a usual interstitial pneumonia pattern in patients with systemic sclerosis-associated interstitial lung disease

被引:2
作者
Bernstein, Elana J. [1 ]
Boin, Francesco [2 ]
Elicker, Brett [3 ]
Luo, Yiming [1 ]
Ren, Yawen [4 ]
Zhang, Meng [5 ]
Varga, John [6 ]
Assassi, Shervin [5 ]
机构
[1] Columbia Univ, Irving Med Ctr, Vagelos Coll Phys & Surg, Dept Med,Div Rheumatol, New York, NY USA
[2] Cedars Sinai Med Ctr, Dept Med, Div Rheumatol, Los Angeles, CA USA
[3] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA
[4] Univ Colorado, Dept Med, Div Rheumatol, Denver, CO USA
[5] Univ Texas Hlth Sci Ctr Houston, UTHlth Houston, Dept Med, Div Rheumatol, Houston, TX USA
[6] Univ Michigan, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
systemic sclerosis; interstitial lung disease; usual interstitial pneumonia; FAM13A; MUC5B; IDIOPATHIC PULMONARY-FIBROSIS; PROMOTER POLYMORPHISM; SUSCEPTIBILITY; GENE; SCLERODERMA; LOCI;
D O I
10.1093/rheumatology/keae573
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The MUC58 promoter single nucleotide polymorphism (SNP) rs35705950 has been associated with idiopathic pulmonary fibrosis (IPF) and RA-related interstitial lung disease (ILD), but not with SSc-ILD. We hypothesized that the MUC58 promoter polymorphism or other IPF susceptibility loci are associated with an increased risk for the uncommon SSc-usual interstitial pneumonia (UIP) endophenotype, rather than SSc-ILD in general. Methods: We performed a cross-sectional study of SSc-ILD patients from four US Scleroderma Programs to investigate the frequency of MUC58 rs35705950 and 12 additional IPF susceptibility loci. SSc-ILD patients were stratified by high resolution chest CT (HRCT) imaging findings into UIP and non-UIP groups. Analysis of HRCTs performed by a thoracic radiologist blinded to participants' characteristics classified each scan as definite UIP, probable UIP, indeterminate or alternative diagnosis, according to American Thoracic Society criteria. Results: Four-hundred and eighty-nine SSc-ILD patients were included; 80% were female and 75% were White. Twenty-three (4.7%) patients had a definite UIP pattern. The MUC58 SNP rs35705950 was not associated with a definite UIP pattern in SSc-ILD. In contrast, patients carrying two copies of the IPF risk gene FAM13A minor allele rs2609255 had significantly higher odds of a definite UIP pattern compared with the other patterns (odds ratio 3.40, 95% CI 1.19-9.70), and compared with an alternative diagnosis (odds ratio 3.65, 95% CI 1.25-10.65). Conclusion: We demonstrated a novel association between FAM13A and SSc-UIP. Contrary to IPF and RA-ILD, the MUC58 promoter polymorphism was not associated with a definite UIP pattern in SSc-ILD.
引用
收藏
页数:6
相关论文
共 50 条
[41]   Clinical significance of histological inflammation in systemic sclerosis-associated interstitial lung disease [J].
Hirota, Shuko ;
Yamano, Yasuhiko ;
Takei, Reoto ;
Fukihara, Jun ;
Sasano, Hajime ;
Matsuda, Toshiaki ;
Kataoka, Kensuke ;
Kimura, Tomoki ;
Sano, Hisao ;
Fukuoka, Junya ;
Johko, Takeshi ;
Kondoh, Yasuhiro .
RESPIRATORY INVESTIGATION, 2025, 63 (02) :233-239
[42]   A retrospective cohort study of outcome in systemic sclerosis-associated interstitial lung disease [J].
Okamoto, Masaki ;
Fujimoto, Kiminori ;
Sadohara, Junko ;
Furuya, Kiyomi ;
Kaieda, Shinjiro ;
Miyamura, Tomoya ;
Suematsu, Eiichi ;
Kitasato, Yasuhiko ;
Kawayama, Tomotaka ;
Ida, Hiroaki ;
Ichiki, Masao ;
Hoshino, Tomoaki .
RESPIRATORY INVESTIGATION, 2016, 54 (06) :445-453
[43]   Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease [J].
Makol, Ashima ;
Nagaraja, Vivek ;
Amadi, Chiemezie ;
Pugashetti, Janelle Vu ;
Caoili, Elaine ;
Khanna, Dinesh .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (06) :613-626
[44]   Are serum biomarkers useful in the management of systemic sclerosis-associated interstitial lung disease? [J].
Proudman, Susanna M. ;
Corte, Tamera J. .
RESPIROLOGY, 2021, 26 (05) :406-408
[45]   Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease [J].
Kim, E. J. ;
Elicker, B. M. ;
Maldonado, F. ;
Webb, W. R. ;
Ryu, J. H. ;
Van Uden, J. H. ;
Lee, J. S. ;
King, T. E., Jr. ;
Collard, H. R. .
EUROPEAN RESPIRATORY JOURNAL, 2010, 35 (06) :1322-1328
[46]   Expert consensus on the management of systemic sclerosis-associated interstitial lung disease [J].
Rahaghi, Franck F. ;
Hsu, Vivien M. ;
Kaner, Robert J. ;
Mayes, Maureen D. ;
Rosas, Ivan O. ;
Saggar, Rajan ;
Steen, Virginia D. ;
Strek, Mary E. ;
Bernstein, Elana J. ;
Bhatt, Nitin ;
Castelino, Flavia V. ;
Chung, Lorinda ;
Domsic, Robyn T. ;
Flaherty, Kevin R. ;
Gupta, Nishant ;
Kahaleh, Bashar ;
Martinez, Fernando J. ;
Morrow, Lee E. ;
Moua, Teng ;
Patel, Nina ;
Shlobin, Oksana A. ;
Southern, Brian D. ;
Volkmann, Elizabeth R. ;
Khanna, Dinesh .
RESPIRATORY RESEARCH, 2023, 24 (01)
[47]   STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease [J].
Khanna, Dinesh ;
Tashkin, Donald P. ;
Wells, Athol U. ;
Seibold, James R. ;
Wax, Stephen ;
Vazquez-Mateo, Cristina ;
Fleuranceau-Morel, Patricia ;
Damian, Doris ;
Denton, Christopher P. .
JOURNAL OF RHEUMATOLOGY, 2021, 48 (08) :1295-1298
[48]   The hidden costs of living with systemic sclerosis-associated interstitial lung disease [J].
Parfrey, Helen .
RESPIROLOGY, 2022, 27 (07) :486-487
[49]   Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease [J].
Meier, C. ;
Freiburghaus, K. ;
Bovet, C. ;
Schniering, J. ;
Allanore, Y. ;
Distler, O. ;
Nakas, C. ;
Maurer, B. .
SCIENTIFIC REPORTS, 2020, 10 (01)
[50]   Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease [J].
Khanna, Dinesh ;
Tashkin, Donald P. ;
Denton, Christopher P. ;
Lubell, Martin W. ;
Vazquez-Mateo, Cristina ;
Wax, Stephen .
RHEUMATOLOGY, 2019, 58 (04) :567-579